Home Mental Wellness Global Pop Icon Nick Jonas Invests in AI-driven Mental Health Company Nurosene

Global Pop Icon Nick Jonas Invests in AI-driven Mental Health Company Nurosene

142
0


“At Nurosene, we continue to bring awareness and push boundaries on how to tackle mental wellness with our NURO app, which provides a unique brain-first approach,” said Ranj Bath, CEO of Nurosene. “We are ecstatic to have Nick as a supporter of Nurosene, investing in our mission to innovate, educate, and build a mental health community to bring recognition and awareness for our mental health solutions globally. Mental health is a systemic concern that we as a global community need to tackle together, to build a generation of better, healthier brains.” 

“I strongly believe that our mental health is paramount to our overall emotional and physical health,” said Nick Jonas. “Nurosene is breaking down barriers and helping to destigmatize mental health, which is why I felt passionate about investing in a company that is prioritizing it and focused on bringing brain health solutions to more people around the world.” 

The investment from Nick Jonas follows Nurosene’s acquisition of innovative pharmatech artificial intelligence leader, NetraMark. NetraMark’s proprietary AI technology will power the company’s data-driven healthtech platform and enable a new era of predictive healthcare that will evolve the company’s mission. NetraMark was recently recognized and asked by Google subsidiary Kaggle to present its leading research in ALS to scientific peers committed to ending ALS.

About Nurosene 

Nurosene provides individuals with tools and technology that empower them to take control of their mental wellness. Our mission is to build the next generation of better, healthier brains by leveraging technological advancements in AI. With our team of experts and partners, Nurosene is positioned at the leading edge of critical research and innovations, striving to disrupt traditional mental wellness treatments.

For more information, visit www.nurosene.com.

About NetraMark

NetraMark Corp., an AI and pharma-tech company, has developed proprietary solutions for pharmaceutical and biotechnology companies. These solutions allow them to leverage small to large data sets in order to optimize clinical trials and drug development. This is accomplished by providing a superior understanding of their patient populations and these insights are also used to develop new drugs and nutraceuticals. NetraMark is a wholly owned subsidiary of Nurosene Health Inc.

For more information, visit www.netramark.com.

Forward-Looking Statements

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation which is based upon Nurosene’s current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. Specifically, this news release contains forward looking statements relating to, among others, activities of the Company’s services and products offered to consumers, future development and goals, including but not limited to those activities in partnership with NetraMark, growth and other initiatives thereto.

Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Nurosene does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Nurosene to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in Nurosene Final Long Form Prospectus dated May 20, 2021 and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in Nurosene Final Long Form Prospectus could cause actual events or results to differ materially from those described in any forward-looking information.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Nurosene Health Inc.

For further information: Blake Sing, Chief Financial Officer, [email protected], (416) 859-8838; KCSA Strategic Communications: Valter Pinto, Managing Director, [email protected], (212) 896-1254

Related Links

https://nurosene.com/



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here